169 completed, 25 terminated, 24 unknown, 23 recruiting. 111 Phase 2, 74 Phase 3, 45 Phase 1, 39 Phase 4, 18 Not applicable.
Follow BID protein, human: new trials by email Literature Review of BID protein, human trials Research Report on BID protein, human
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CBD Supplementation in Brazilian Jiu-Jitsu Athletes CBD Isolate 100mg BID, Placebo - Pro and Anti Inflamatory Cytokines, Pain | Phase 2 / Phase 3 | Not yet recruiting | Associação Pan-Americana Multidisciplinar de Endocanabinologia | 100 | 2027-01-01 | 2026-07-27 |
| Aom0304 in Adult Patients With Symptomatic Hypertrophic Cardiomyopathy QG101-23-0 enteric coated capsule (60/120/240/360 mg BID), QG101-23-0 enteric coated capsule (120/240/360/480mg BID) - Hypertrophic Cardiomyopathy (HCM), Obstructive HCM (oHCM) | Phase 2 | Not yet recruiting | Amckaus PTY LTD. | 56 | 2026-10-01 | 2026-06-30 |
| Optimal Anti-Thrombotic Management Following Percutaneous Left Atrial Appendage Occlusion Half-Dose of novel OAC, Low-dose ASA - Atrial Fibrillation (AF) | Phase 3 | Recruiting | Texas Cardiac Arrhythmia Research Foundation | 234 | 2026-09-01 | 2026-10-05 |
| A Clinical Trial Evaluating Fecal Microbiota Transplantation (FMT) in Adolescents With ADHD Fecal Microbiota Transplant (FMT), Nitazoxanide 500mg BID, Vancomycin 250mg BID - ADHD, ADHD - Attention Deficit Disorder With Hyperactivity | Phase 2 | Not yet recruiting | University of Calgary | 64 | 2026-08-31 | 2026-09-10 |
| Dose Escalation Study to Assess Safety, Tolerability, and Efficacy of Budiodarone Treatment With Non-permanent Atrial Fibrillation Budiodarone 200 mg BID, Budiodarone 400 mg BID, Budiodarone 600 mg BID - Atrial Fibrillation (AF), Paroxysmal AF | Phase 2 | Recruiting | Xyra, LLC | 100 | 2026-08-06 | 2026-08-28 |
| Optimizing H. Pylori Eradication Regimen Under Intensified Acid Suppression Keverprazan Hydrochloride 20 mg TID, Minocycline 100 mg (10-Day Regimen), Keverprazan Hydrochloride 20 mg BID - HELICOBACTER PYLORI INFECTIONS | Phase 4 | Not yet recruiting | Qilu Hospital of Shandong University | 316 | 2026-08-01 | 2026-08-06 |
| Study of XNW5004 Tablets in Advanced Prostate Cancer XNW5004 1200 mg BID in Combination with Abiraterone plus Prednisone, XNW5004 1200 mg BID in Combination with Docetaxel plus Prednisone, XNW5004 800 mg or 1200 mg (1:1 randomization), PO, BID; Abiraterone 1000 mg PO, taken on an empty stomach at least 1 hour before and at least 2 hours after a meal, QD; plus Prednisone 5 mg PO BID - Advanced Prostate Cancer | Phase 2 | Not yet recruiting | Evopoint Biosciences Inc. | 242 | 2026-07-13 | 2026-07-28 |
| Efficacy of Asciminib in Chronic Phase CML Patients With T315I Mutations asciminib 200 mg BID - Chronic Myeloid Leukemia (CML) | Phase 2 | Active not recruiting | Thomas Ernst, PD Dr. med. | 50 | 2026-06-22 | 2026-08-27 |
| A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia AP306 75 mg BID, AP306 125 mg BID, AP306 150 mg BID - Hyperphosphatemia, Chronic Kidney Disease Requiring Chronic Dialysis | Phase 2 | Recruiting | R1 Therapeutics | 168 | 2026-06-01 | 2026-08-26 |
| CLOT-LESS - CLOsure Tailored: LEss Antithrombotic Strategy After LAAC for Stroke Prevention Left Atrial Appendage Closure, Apixaban 2.5 mg BID, Standard-dose DOAC - Atrial Fibrillation, Stroke Prevention in Patients With Atrial Fibrillation | Recruiting | National Medical Research Center for Therapy and Preventive Medicine | 464 | 2026-04-01 | 2026-05-08 | |
| The Effects of Conventional Therapy on Tinnitus, Disability, and Quality of Life in Patients With Tinnitus Neural Therapy of Huneke, Betahistine 24 mg bid (Betaserc) - Tinnitus, Neural Therapy of Huneke | Not applicable | Not yet recruiting | Sisli Hamidiye Etfal Training and Research Hospital | 30 | 2026-03-01 | 2026-03-23 |
| Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia Evenamide 15 mg bid, Placebo - Treatment-resistant Schizophrenia | Phase 3 | Recruiting | Newron Pharmaceuticals SPA | 400 | 2026-01-23 | 2026-09-10 |
| A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults Tenapanor 5 mg BID, Tenapanor 25 mg BID, Tenapanor 50 mg BID - Chronic Idiopathic Constipation (CIC) | Phase 3 | Recruiting | Ardelyx | 692 | 2026-01-13 | 2026-06-04 |
| Evaluation of Safety, Tolerability and Preliminary Efficacy of Etrinabdione in Patients With Peripheral Arterial Disease Etribnabdione 25 mg BID, Etribnabdione 50 mg BID - Peripheral Arterial Disease | Phase 2 | Not yet recruiting | VivaCell Biotechnology España | 30 | 2026-01-01 | 2025-09-17 |
| Cilostazol for Preventing Delayed Cerebral Ischemia in Aneurysmal Subarachnoid Hemorrhage Cilostazol 100 mg BID, placebo - Aneurysmal Subarachnoid Hemorrhage | Phase 3 | Recruiting | Beijing Tiantan Hospital | 380 | 2025-12-06 | 2026-10-16 |
| Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis GLK-321 low dose BID, GLK-321 mid dose BID, GLK-321 high dose BID - Demodex Blepharitis | Phase 2 | Recruiting | Glaukos Corporation | 250 | 2025-12-05 | 2026-02-27 |
| PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS Cromolyn Sodium (34.2 mg BID), Cromolyn Sodium (17.1 mg BID), Placebo - Amyotrophic Lateral Sclerosis (ALS) | Phase 2 | Recruiting | PhenoNet, Inc. | 105 | 2025-11-25 | 2026-07-23 |
| Tegoprazan Plus Amoxicillin BID vs TID Regimens for H. Pylori Eradication（Frequency Adjusted Same-dose Therapy for H. Pylori） Tegoprazan 50 mg, Amoxicillin 1 g TID, Amoxicillin 1.5 g BID - HELICOBACTER PYLORI INFECTIONS | Phase 4 | Not yet recruiting | First People's Hospital of Hangzhou | 240 | 2025-11-20 | 2025-11-21 |
| Smoking Cessation Trial in Recurrent Acute Pancreatitis and Chronic Pancreatitis Standard Varenicline Dosing (1 mg BID), Bupropion 150 mg twice daily, Increased Varenicline Dosing (1mg TID) - Pancreatitis, Chronic, Pancreatitis, Acute | Phase 2 | Withdrawn | Mayo Clinic | 2025-11-06 | 2026-07-07 | |
| Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer Olaparib (300 mg BID), Pembrolizumab, 177Lu-PSMA-I&T - Metastatic Castrate Resistant Prostate Cancer (mCRPC) | Phase 1 | Not yet recruiting | Peter MacCallum Cancer Centre, Australia | 20 | 2025-11-01 | 2025-07-29 |
Showing 20 of 277. Sign in to see all of them.
Asthma (15) · Diabetes Mellitus, Type 2 (10) · Pulmonary Disease, Chronic Obstructive (9) · Ocular Hypertension (8) · Glaucoma, Open-Angle (7) · Hypertension (7) · Gastroesophageal Reflux (6) · Obesity (6) · Peripheral Arterial Disease (6) · Cardiovascular Diseases (5) · Diabetes Mellitus (5) · Glaucoma (5) · Schizophrenia (5) · Acquired Immunodeficiency Syndrome (4) · Eosinophilic Esophagitis (4)
GlaxoSmithKline (10) · Pfizer (9) · AstraZeneca (7) · Boehringer Ingelheim (6) · Haisco Pharmaceutical Group Co., Ltd. (6) · Merck Sharp & Dohme LLC (6) · Aerie Pharmaceuticals (4) · Eisai Inc. (4) · Novartis Pharmaceuticals (4) · Organon and Co (4) · Seoul National University Hospital (4) · Bausch & Lomb Incorporated (3) · Bayer (3) · NicOx (3) · XenoPort, Inc. (3)
United States (129) · China (36) · Germany (32) · Canada (30) · South Korea (28) · Spain (21) · France (20) · Italy (18) · Poland (18) · Czechia (15) · Russia (14) · United Kingdom (14) · Argentina (12) · Australia (12) · Hungary (11)
Theresa Heah, MD (4) · Esther Garcia, MD (3) · Carol J Fabian, MD (2) · Luz Pascual, MD MPH (2) · Ralph Mueller, PhD (2)
PMID 23661689, PMID 27206567, PMID 27659698, PMID 27888609, PMID 27116910, PMID 10049409, PMID 10865927, PMID 16140398, PMID 16329022, PMID 17015867, PMID 17636626, PMID 17660026, PMID 17919504, PMID 1830180, PMID 18399898, PMID 18779447, PMID 19506373, PMID 20150545, PMID 20350366, PMID 20642206, PMID 20647200, PMID 20678306, PMID 20730060, PMID 20823393, PMID 20874458, PMID 20920599, PMID 21125444, PMID 21190985, PMID 21285388, PMID 21612611, PMID 21640651, PMID 21677432, PMID 21795446, PMID 21828036, PMID 21903737, PMID 21947244, PMID 22007612, PMID 22020082, PMID 22369287, PMID 22421927, PMID 22441743, PMID 22497752, PMID 22818144, PMID 22829927, PMID 22837373, PMID 22879655, PMID 22913891, PMID 23474153, PMID 23563576, PMID 23567357
2009 (4), 2008 (3), 2014 (2), 2017 (2), 2018 (2), 2019 (2), 2023 (2), 2025 (2), 2015 (1), P50HL056385 (1), R01AI120765 (1), R01CA296186 (1), R41MH083436 (1), U10HL098115 (1), UL1RR024982 (1)